Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Cost-effectiveness analysis of human papillomavirus vaccination in South Africa accounting for human immunodeficiency virus prevalence

Fig. 3

One-way sensitivity analyses: (a) base case analysis, (b) scenario analysis. BC, base case; CI, confidence interval; CIN, cervical intraepithelial neoplasia; CIN1/2/3, CIN grade 1, 2 or 3; GDP, gross domestic product; HIV, human immunodeficiency virus; HIV-, HIV-negative; HIV+, HIV-positive; HPV, human papillomavirus; ICER, incremental cost-effectiveness ratio; Pap, Papanicolaou test; pop, population

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us